| Document |
Document Title |
|
JP3919836B2 |
To obtain a suppressant for relapse and keloplasty in a postoperative anastomosed part of inflammatory bowel diseases, comprising a fibrin paste containing a medicine capable of suppressing the production of inflammatory cytokine and leu...
|
|
JP3923290B2 |
To obtain a composition and to provide a method for effectively inhibition fibrosis and scar formation. Anionic polymers effectively inhibit cell invasion associated with unfavorable healing process and the inhibiting effect of the anion...
|
|
JP2007512955A |
A silver composition containing sparingly soluble silver compounds and a method of coating the composition on a substrate is disclosed.
|
|
JP2007119498A |
To provide a composition for keeping protuberance of epithelium, easily performable of injecting a solution through a fine catheter and capable of keeping the protuberance of the epithelium high.The composition for keeping protuberance o...
|
|
JP2007119489A |
To provide a new cyclosporine derivative which possess enhanced efficacy and modified pharmacokinetic and pharmacodynamic parameters.The invention discloses the cyclosporine derivative which possess enhanced efficacy and reduced toxicity...
|
|
JP2007510732A |
This invention is directed generally to proteinase (also known as "protease") inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also kn...
|
|
JP2007509643A |
This invention discloses methods to attach and grow a monolayer of cultured human corneal endothelial cells onto the endothelial side of the stroma synthesized from biopolymer to generate a more bio-equivalent artificial cornea. The appr...
|
|
JP2007508318A |
The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histor...
|
|
JP2007082422A |
To provide dendritic cells excellent in migration and infiltration capabilities, and also excellent in the application for an immunocyte treatment instead of the dendritic cells differentiated under a low oxygen state such as a cancer ti...
|
|
JP2007508269A |
The invention relates to the compounds of formula I, a process for their production and their use as anti-inflammatory agents.
|
|
JP2007507528A |
Compositions and methods of treating conditions requiring oxygen or resulting from molecular damage induced by reactive metabolites, hypoxia or ischema. Tetrameric oxygen is administered alone as an aqueous solution or in conjunction wit...
|
|
JP2007507551A |
2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: wherein R is a member selected from the group consisting of H and C1-6 alkyl; R1 is a member selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C3-...
|
|
JP2007505697A |
The present invention is directed to implants that include therapeutic molecules bonded to their surfaces. The therapeutic molecules interact with cells that are adjacent, near, or adhering to the implant. The covalently-bonded therapeut...
|
|
JP2007505621A |
The invention provides fusion polypeptides comprising protein transduction domains and osteoinductive polypeptides, as well as methods of using such polypeptides to induce osteogenesis and to promote proteoglycan synthesis. The invention...
|
|
JP2007505939A |
The invention relates to a combination therapy for treating patients suffering from diseases characterized by cell proliferation and infiltration of inflammatory cells, coronary diseases, hypertension, renal diseases, diabetes, or ocular...
|
|
JP2007505112A |
The present invention provides methods of preventing or alleviating sympathetically-enhanced conditions, neurological conditions, ocular conditions and chronic pain without concomitant sedation by peripherally administering to a subject ...
|
|
JP2007504273A |
Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions.
|
|
JP2007504116A |
The invention describes the use of surfactant comprising phospholipids and pulmonary surfactant proteins for the treatment of surgical adhesions.
|
|
JP2007503426A |
Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formul...
|
|
JP3882943B2 |
PCT No. PCT/EP96/01702 Sec. 371 Date Jan. 27, 1999 Sec. 102(e) Date Jan. 27, 1999 PCT Filed Apr. 24, 1996 PCT Pub. No. WO97/39765 PCT Pub. Date Oct. 30, 1997The present invention relates to the use of Component B as cicatrizant, in parti...
|
|
JP2007031454A |
To provide a method for perioperatively inhibiting pain and inflammation or spasm, or pain, inflammation and spasm at wounds.In this method, a dilute concentration solution in a physiologic carrier including a plurality of inhibitors sel...
|
|
JP2007501798A |
Use of a natural cytokine mixture (NCM) including the cytokines IL-1, IL-2, IL-6, IL-8, IL-12, IFN-gamma, TNF-alpha, GM-CSF and G-CSF, for immunotherapy of a cancer patient in a dosage regime comprising (i) administration of the NCM in a...
|
|
JP2007501209A |
Boranocarbonates are described for administration to a human or other mammal for delivery of carbon monoxide. The boranocarbonate is a compound or ion adapted to make CO available for physiological effect, and may be administered with a ...
|
|
JP3872290B2 |
A method for indirectly stimulating a vagus nerve of a patient includes the steps of positioning one or more electrodes in the vicinity of the vagus nerve and then actuating the electrode(s) to create an electrical field for stimulating ...
|
|
JP2007500725A |
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activit...
|
|
JP2007008966A |
To provide a method for treating and preventing cancers of a specific type, such as primary and metastatic cancers and cancers refractory or resistant to conventional chemotherapy.The medicinal composition for preventing and treating can...
|
|
JPWO2005037292A1 |
The present invention provides a mucosal swelling solution for endoscopic surgery, which comprises a sugar chain-containing chitosan derivative. When the composition of the present invention is used as a submucosal bulge for endoscopic s...
|
|
JP2006345867A |
To provide a nuclear transport agent, a gene transfer system comprising the nuclear transport agent, a method of transporting DNA into the nucleus of eukaryotic cells using the nuclear transport agent and the use of the nuclear transport...
|
|
JP3862361B2 |
To obtain the subject new peptide having a specific amino acid sequence, having actions such as a cell proliferation-stimulating action and a cell-adhering action, and capable of being fixed to substrates to use the peptide as a medical ...
|
|
JP2006527228A |
The invention relates to selected anthranylamide pyridones that inhibit VEGFR-2 and VEGFR-3 and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis.
|
|
JPWO2005011718A1 |
The present invention provides an anti-stress agent characterized by containing an aroma component of coffee or tea as an active ingredient, which can effectively prevent or reduce various symptoms associated with stress, and is safer an...
|
|
JP2006525031A |
The invention relates to novel apoptosis-associated nucleic acids and polypeptides and methods for use thereof, including methods of treatment of disorders associated with aberrant cellular proliferation, differentiation, or degeneration...
|
|
JP2006522746A |
The use of substituted amides for modulating the activity of 11²-hydroxysteroid dehydrogenase type 1 (11²HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, thei...
|
|
JP2006522750A |
Combination therapy comprising the administration of an 11ss-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia...
|
|
JP3828597B2 |
To prepare the subject compound useful for the treatment or prophylaxis of cardiac infarct, angina pectoris, arrhythmia, ischemic conditions, apoplexy, shock states, atherosclerosis, late diabetic complications, carcinoses, fibrotic dise...
|
|
JP2006254929A |
To provide an antiadhesive material strong against physical bending relating to the antiadhesive material, relating to the a flexible antiadhesive material especially excellent in handleability to be more in details.A water insoluble car...
|
|
JP2006522140A |
Agents and methods for treatment of adhesions and fibrotic diseases, through the release of drugs that retard or inhibit fibrotic tissue production. A method for releasing fibrotic tissue-inhibiting agents from a polymer is provided. The...
|
|
JP2006246853A |
To provide a cryopreserving agent for cryopreserving bone marrow cells, cord blood cells or peripheral stem cells without degradation and an activity-maintaining agent for bone marrow cells, cord blood cells or peripheral stem cells for ...
|
|
JP2006249085A |
To provide a new platform antibody composition exhibiting improved chemical and/or physical stability.A new composition of a human IgG2 antibody contains a chelating agent. Further, the new antibody composition which exhibits the improve...
|
|
JP2006520796A |
Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-1...
|
|
JP3820148B2 |
The invention relates to sulfonyl amine derivatives of formula IA wherein R5A, X1, X2, R9 and R10 are as defined herein, which derivatives are useful as bradykinin B1 receptor antagonists.
|
|
JP2006519766A |
A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that up...
|
|
JP2006519681A |
The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous t...
|
|
JP2006219458A |
To provide a medicine and/or food and drink having preventing and/or treating effect on ischemic enteropathy, having low side action and high safety and ingestible over a long period.The agent for the prevention and/or treatment of ische...
|
|
JP2006518583A |
The invention relates to fusion proteins consisting of a wild-type IL-15 and a IgG-Fc fragment, apart from a mouse IgG2b fragment, nucleic acids encoding said proteins, vectors, modified cells, and also to the use thereof for preparing d...
|
|
JPWO2005002590A1 |
In metabolic bone diseases such as osteoporosis, bone strength decreases due to a decrease in bone mass, and pain such as low back pain and fractures frequently occur. Therefore, there is a strong demand for the creation of a drug capabl...
|
|
JP3805981B2 |
(A) A method is claimed for treatment of human patients with vascular occlusive and arterial thromboembolic disorders, comprising administering a dosage of 0.01 to 0.05 mg/kg/hr of activated protein C (APC). Also claimed are: (B) a unit ...
|
|
JP3806427B2 |
The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The co...
|
|
JP2002519156A5 |
|
|
JP2006517953A |
The compounds of formula I in which R1, R2, R3, R4 and R5 have the meanings as given in the description are novel effective antiinflammatory compounds.
|
